Serum ACE activity and plasma ACE concentration in patients with SARS-CoV-2 infection

7Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Significant controversy has arisen over the role of the renin-angiotensin-aldosterone system (RAAS) in COVID-19 pathophysiology. In this prospective, observational study, we evaluated plasma angiotensin converting enzyme (ACE) concentration and serum ACE activity in 52 adults with laboratory-confirmed SARS-CoV-2 infection and 27 non-COVID-19 sick controls. No significant differences were observed in ACE activity in COVID-19 patients versus non-COVID-19 sick controls (41.1 [interquartile range (IQR): 23.0–55.2] vs. 42.9 [IQR 13.6–74.2] U/L, p =.649, respectively). Similarly, no differences were observed in ACE concentration in COVID-19 patients versus non-COVID-19 sick controls (108.4 [IQR: 95.8–142.2] vs. 133.8 [IQR: 100.2–173.7] μg/L, p =.059, respectively). Neither ACE activity (p =.751), nor ACE concentration (p =.283) was associated with COVID-19 severity. Moreover, neither ACE activity, nor ACE concentration was correlated with any inflammatory biomarkers.

Cite

CITATION STYLE

APA

Henry, B. M., Benoit, J. L., Rose, J., de Oliveira, M. H. S., Lippi, G., & Benoit, S. W. (2021). Serum ACE activity and plasma ACE concentration in patients with SARS-CoV-2 infection. Scandinavian Journal of Clinical and Laboratory Investigation, 81(4), 272–275. https://doi.org/10.1080/00365513.2021.1926536

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free